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Letters to the Editor
detection of bacterial DNA by polymerase chain reaction tech-
nique in blood. In addition, more sophisticated techniques using
ﬂuorescent markers to monitor trans-epithelial permeability and
providing us with real-time information with in vivo imaging
could be developed. The combination of the approaches
suggested above will lead to a more global understanding of
the pathophysiology of enterocyte TJs in human liver cirrhosis
and to the discovery of more speciﬁc targets (disrupting a
signaling pathway, interfering with a regulatory RNA or protein
molecule, others) and will likely lead to more effective and
potentially individualized pharmacological control of intestinal
hyperpermeability, thus preventing the endotoxin-associated
systemic complications and improving clinical outcome..
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Athens, GreeceReply to: ‘‘Uncovering the molecular events associated with increased
intestinal permeability in liver cirrhosis: The pivotal role
of enterocyte tight junctions and future perspectives’’To the Editor:
We thank Assimakopoulos and colleagues for their interest in our
recent article [1]. As suggested, important efforts are being made
to understand why the intestinal barrier fails in cirrhosis and the
mechanism by which viable bacteria translocate from the gastro-
intestinal tract.
In our study, we assessed the following:
Firstly, we studied the morphology and function of the intesti-
nal barrier in decompensated and compensated ASH/NASH cir-
rhotic patients. We could show that the morphology of the
intestinal barrier was intact at the ultrastructural level, suggesting
that permeabilitywas functionally altered andnot just secondarily
increased due towidened intracellular junctions induced by portal
hypertension [2,3]. At a functional level, we could indeed conﬁrm
that transepithelial resistance was decreased and permeability
increased inpatientswithdecompensated cirrhosis.We fully agree
with the comments by Assimakopoulos et al. that emphasize the
important role of TJ proteins in intestinal barrier function in cirrho-
sis as demonstrated in their recent study [4]. The difference in the
implicated TJ proteins between our study [1] and that of Assimak-1146 Journal of Hepatology 2013 vol. 59 j 1143–1149
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opoulos et al. [4] can partly be explainedby thepatient populations
included in each study and the TJ proteins analysed. Their study
included patients with liver cirrhosis from various aetiologies
including viral infection, which were deliberately excluded from
our study. It hasbeenshownthat theexpressionof claudinproteins
changes during development, differentiation, and in disease, in
response to stressors – including cytokines – in intestina
epithelial cells [5,6]. Thus speciﬁc aetiological factors might
inﬂuence TJ expression.
Secondly, we assessed the role of intestinal macrophages in
cirrhosis. Intestinal macrophages have been shown to be
activated in Crohn’s disease [7] and in HIV enteropathy (manu-
script submitted) and have been shown to produce inﬂammatory
cytokines. Barrier defects are caused by disruption of normal
regulatory mechanisms that control gene expression, tight junc-
tion structure and cytoskeletal signalling [8]. We could show
for the ﬁrst time that intestinal macrophages are activated in
decompensated cirrhosis that may inﬂuence enterocyte TJ regula-
tion. Speciﬁcally, we could demonstrate an increase in IL-6 and
NO production, which have been previously shown to inﬂuence
intestinal permeability in inﬂammatory conditions, such as IBD
and necrotizing enterocolitis [6–8]. Although we have identiﬁed
important mechanisms associated with macrophage activation
in cirrhosis, it remains unclear to what extent these factors are
responsible for translocation of viable bacteria. Such studies
should be conducted using epithelial cultures exposed to
intestinal macrophages obtained from patients with liver disease
These studies are currently ongoing in our laboratory.
The data and comments presented by Assimakopoulos et al
highlight our ﬁndings that intestinal barrier TJ proteins play an
important role in bacterial translocation in liver cirrhosis
Although we have identiﬁed activated intestinal macrophages
as potential players in the pathogenesis of BT in cirrhosis, we
have only reached the tip of the iceberg. Additional human ani-
mal and culture studies as well as more sophisticated methods
of measuring BT will shed light on how the intestinal epithelial
barrier, gut microbiota, and immune system interact and inﬂu-
ence disease progression in cirrhosis.Intestinal GATA4 deﬁciency induc
factor 15 expression and repres
To the Editor:
We have recently reported that conditional deletion of intestinal
GATA4 leads to an increased protection from obesity-associated
hepatic steatosis [1]. Using two independent murine models of
diet-induced hepatic steatosis, we demonstrated that intestine
speciﬁc GATA4 knockout (GATA4iKO) mice are protected from
high fat diet-induced hepatic steatosis. Our ﬁndings showed that
intestinal GATA4 deﬁciency was protective only in case where
hepatic de novo lipogenesis was involved, secondary to insulin
resistance. GATA4iKO mice were not protected upon induction
of steatosis via dietary deﬁciency of methionine and choline.
Methionine and choline-deﬁcient diet leads to hepatic steatosis
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ses hepatic gluconeogenesis
by suppressing VLDL release and beta-oxidation and does not sig-
niﬁcantly impact de novo lipogenesis. The underlying mechanism
for the observed beneﬁt is the ectopic upregulation of GLP-1 and
higher number of GLP-1 producing L-cells in the proximal intes-
tine of GATA4iKO mice.
Previous studies have shown that the levels of the important
enterokine ﬁbroblast growth factor 15 (FGF-15) are also upregu-
lated several fold in the proximal intestine of GATA4iKO mice
[2,3]. Under physiological conditions, transcript levels of intesti-
nal FGF-15 are restricted to the mucosa of the ileum and are sen-
sitive to bile acid availability and consequent activation of
farnesoid X receptor (FXR). However, it is not clear whether the
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